

AQUINOX PHARMACEUTICALS, INC

Reported by **LEVITT DANIEL J**

FORM 4

(Statement of Changes in Beneficial Ownership)

Filed 05/10/17 for the Period Ending 05/08/17

Telephone 604-629-9223

CIK 0001404644

Symbol AQXP

Fiscal Year 12/31





[] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *				2.	2. Issuer Name and Ticker or Trading Symbol					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
LEVITT DANIEL J					AQUINOX PHARMACEUTICALS, INC [AQXP]						X Director	,,	1	0% Owner	
(Last) (First) (Middle)					3. Date of Earliest Transaction (MM/DD/YYYY)						Officer (give title below)Other (specify below)				
C/O AQUIN PHARMAC GREAT NO	EUTICA			- 887			5/8	8/2017	7						
(Street)				4.	4. If Amendment, Date Original Filed (MM/DD/YYYY)					6. Individual or Joint/Group Filing (Check Applicable Line)					
VANCOUVER, A1 V5T 4T5 (City) (State) (Zip)										_ X _ Form filed by One Reporting Person _ Form filed by More than One Reporting Person					
			Table I	- Non-De	erivat	tive Secu	rities Ac	cquired	, Disposed	of, or Ben	eficially Own	ed			
1.Title of Security (Instr. 3) 2. Trans. I			. Trans. Date	ate Execution Date, if any 3. Trans. Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) Code V Amount (D) Price 3. Trans. Code (Instr. 8) 4. Securities Acquired (A) Following Reported Transaction(s) (Instr. 3 and 4)						7. Nature of Indirect Beneficial Ownership (Instr. 4)					
	Tab	ole II - Dei	rivative S	Securities	Ben	eficially (Owned ((<i>e.g.</i> , p	uts, calls, v	warrants,	options, conve	rtible sec	urities)		
(Instr. 3)	Conversion or Exercise Price of Derivative	3. Trans. Date	3A. Deeme Execution Date, if any	(Instr. 8)		ode 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and 2. Securities Uperivative S (Instr. 3 and	nderlying ecurity	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned	Form of Derivative Security:	11. Nature of Indirect Beneficial Ownership (Instr. 4)
	Security			Code	V	(A)	(D)	Date Exercisab	Expiration Date	Title	Amount or Number of Shares		Following Reported Transaction(s) (Instr. 4)	Direct (D) or Indirect (I) (Instr. 4)	
Stock Option (Right to Buy)	\$13.74	5/8/2017		A		9000		<u>(1)</u>	5/7/2027	Common Stock	9000	\$0.00	9000	D	

Explanation of Responses:

(1) The shares subject to this option shall vest and become exercisable at a rate of 1/12th of the total number of shares underlying the options on the one-month anniversary of May 8, 2017 (the "Vesting Commencement Date") and 1/12th of the total number of shares underlying the options each monthly anniversary of the Vesting Commencement Date thereafter for so long as the recipient of the option provides continuous service to the issuer, such that the total number of shares underlying the options shall be fully vested on the one-year anniversary of the Vesting Commencement Date.

Reporting Owners

Reporting Owner Name / Address	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
LEVITT DANIEL J							
C/O AQUINOX PHARMACEUTICALS, INC.	X						
450 - 887 GREAT NORTHERN WAY							
VANCOUVER, A1 V5T 4T5							

Signatures

/s/ Daniel J. Levitt 5/10/2017

**Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.